BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

Journal of Psychopharmacology

Volumn 30, Issue 8, 2016, Pages 717-748

  Cooper, Stephen J ^a,b   Reynolds, Gavin P ^a,c   Barnes, T R E ^d   England, E ^e   Haddad, P M ^f,g   Heald, A ^f,h   Holt, R I G ⁱ   Lingford Hughes, A ^d,j   Osborn, D ^k   McGowan, O ^l   Patel, M X ^m   Paton, C ^b,n   Reid, P ^o   Shiers, D ^b   Smith, J ^p  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e Laurie Pike Health Centre ^*  (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h LEIGHTON HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l HAIRMYRES HOSPITAL   (United Kingdom)

^m KING'S COLLEGE LONDON   (United Kingdom)

ⁿ OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^o RETHINK MENTAL ILLNESS   (United Kingdom)

^p UNIVERSITY OF WORCESTER   (United Kingdom)

more..

Author keywords

Alcohol misuse; antipsychotic; aripiprazole; cardiovascular disease; diabetes; dyslipidaemia; guidelines; interventions for weight gain; lifestyle; metformin; obesity; overweight; psychosis; risk assessment; schizophrenia; smoking cessation; switching

Indexed keywords

ARIPIPRAZOLE; MELATONIN; METFORMIN; NEUROLEPTIC AGENT; REBOXETINE; TOPIRAMATE; ZONISAMIDE;

ALCOHOLISM; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; HEALTH; HEALTH CARE DELIVERY; HEALTH HAZARD; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MEDICATION THERAPY MANAGEMENT; METABOLIC DISORDER; NICOTINE REPLACEMENT THERAPY; OBESITY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SECONDARY HEALTH CARE; SMOKING; TREATMENT PLANNING; WEIGHT GAIN; CARDIOVASCULAR DISEASE; COMPLICATION;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; OBESITY; OVERWEIGHT; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84978766607     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881116645254     Document Type: Article

References (209)

1. Afshar H, Roohafza H, Mousavi G, et al. (2009) Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 23: 157-162.
2. Ahmed AT, Warton EM, Schaefer CA, et al. (2013) The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord 15: 753-763.
3. Alberti KG, Zimmet P, Shaw J, et al. (2005) IDF Epidemiology Task Force Consensus Group. The metabolic syndrome new worldwide definition. Lancet 366: 1059-1062.
4. Allison DB, Mentore JL, Heo M, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
5. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. (2006) Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 67: 1253-1260.
6. Alvarez-Jimenez M, Martlnez-Garcla O, Perez-Iglesias R, et al. (2010) Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res 116: 16-19.
7. Aronne LJ, Wadden T, Isoldi KK, et al. (2009) When prevention fails: obesity treatment strategies. Am J Med 122 (4) (Suppl 1): S24-S32.
8. Arranz B, Rosel P, Ramirez N, et al. (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65: 1335-1342.
9. Barnes TRE, Mutsatsa SH, Hutton SB, et al. (2006) Comorbid substance use and age of onset in schizophrenia: the West London first episode study. Br J Psychiatry 188: 237-242.
10. Barnes TRE, Paton C, Cavanagh M-R, et al.; on behalf of the UK Prescribing Observatory for Mental Health (2007) A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schiz Bull 33: 1397-1403.
11. Barnes TR, Paton C, Hancock E, et al.; on behalf of the UK Prescribing Observatory for Mental Health (2008) Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 118: 26-33.
12. Barnes TRE, Bhatti SF, Adroer R, et al. (2015) Screening for the metabolic side effects of antipsychotic medication: findings from a 6-year quality improvement programme in the UK. BMJ Open 5: e007633.
13. Barnett AH, Mackin P, Chaudhry, et al. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 21: 357-373.
14. Barr RS, Culhane MA, Jubelt LE, et al. (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33: 480-490.
15. Bartels SJ, Pratt SI, Aschbrenner KA, et al. (2013) Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. Psychiatr Serv 64: 729-736.
16. Bartels SJ, Pratt SI, Aschbrenner KA, et al. (2014) Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 172: 344-352.
17. Bennett ME, Wilson AL, Genderson M, et al. (2013) Smoking cessation in people with schizophrenia. Curr Drug Abuse Rev 13: 180-190.
18. Bobo WV, Cooper WO, Stein M, et al. (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70: 1067-1075.
19. Boussageon R, Gueyffier F, Cornu C, (2016) Metformin as firstline treatment for type 2 diabetes: are we sure? BMJ 352: h6748.
20. Breese CR, Lee MJ, Adams CE, et al. (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
21. British Cardiac Society (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (Suppl v): v1-v52. doi: 10.1136/hrt.2005.079988
22. Brown S, (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171: 502-508.
23. Bruins J, Jorg F, Bruggeman R, et al. (2014) The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS ONE 9: e112276.
24. Caemmerer J, Correll CU, Maayan L, (2012) Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 140: 159-168.
25. Casey DE, Haupt DW, Newcomer JW, et al. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl 7): 4-18.
26. Cohen J, (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale: Lawrence Erlbaum Associates.
27. Collins GS, Altman DG, (2012) Predicting the 10-year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 344: e4181.
28. Connolly V, Unwin N, Sherriff P, et al. (2000) Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health 54: 173-177.
29. Correll CU, Manu P, Olshanskiy V, et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302: 1765-1773.
30. Correll CU, Robinson DG, Schooler NR, (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. JAMA Psychiatry 71: 1350-1363.
31. Crawford MJ, Jayakumar S, Lemmey SJ, et al. (2014) Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry 205: 473-477.
32. Curtis J, Newall HD, Samaras K, (2012) The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry 6: 347-353.
33. Curtis J, Watkins A, Rosenbaum S, et al. (2015) Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry. Epub ahead of print 26 2015. DOI: 10.1111/eip.12230.
34. D'Agostino RB, Vasan RS, Pencina MJ, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117: 743-753.
35. Das C, Mendez G, Jagasia S, et al. (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24: 225-239.
36. Daumit GL, Goldberg RW, Anthony C, (2005) Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 193: 641-646.
37. Daumit GL, Dickerson FB, Wang N, et al. (2013) A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 368: 1594-1602.
38. Deberdt W, Winokur A, Cavazzoni PA, et al. (2005) Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15: 13-21.
39. De Hert M, Schreurs V, Vancampfort D, et al. (2009a) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8: 15-22.
40. De Hert M, Dekker JM, Wood D, et al. (2009b) Cardiovascular disease and diabetes in people with severe mental illness: position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24: 412-424.
41. De Hert M, Correll CU, Bobes J, et al. (2011) Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52-77.
42. Department of Health (2011) No Health Without Mental Health: A Cross-Government Mental Health Outcomes Strategy for People of All Ages. London: Department of Health. Available at: www.gov.uk/government/publications/no-health-without-mental-health-a-cross-government-outcomes-strategy (. accessed 3 April 2016).
43. Department of Health (2016) Alcohol Guidelines Review-Report from the guidelines development group to the UK Chief Medical Officers. London: Department of Health. Available at: www.gov.uk/government/consultations/health-risks-from-alcohol-new-guidelines (. accessed 3 April 2016).
44. Diabetes Prevention Program Research Group (2002) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374: 1677-1686.
45. Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35: 731-737.
46. Dombrowsi SU, Avenell A, Sniehotta FF, (2010) Behavioural interventions for obese adults with additional risk factors for morbidity: systematic review of effects on behaviour, weight and disease risk factors. Obes Facts 3: 377-396.
47. Fakhoury WK, Wright D, Wallace M, (2001) Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 16: 153-162.
48. Fan X, Borba CPC, Copeland P, et al. (2013) Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 127: 217-226.
49. Faulkner G, Cohn T, Remington G, et al. (2007) Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res 90: 174-178.
50. Fernandez-Sola J, (2015) Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol 12: 576-587. DOI: 10.1038/nrcardio.2015.91.
51. Ferrier IN, Arendt J, Johnstone EC, et al. (1982) Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clin Endocrinol 17: 181-187.
52. Fleischhacker WW, Heikkinen ME, Olie J-P, et al. (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13: 1115-1125.
53. Fleischhacker WW, Siu CO, Bodén R, EUFEST study group (2013) Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 16: 987-995.
54. Foley DL, Morley KI, (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68: 609-616.
55. Fontbonne A, Charles A, Juhan-Vague I, et al. (1996) The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 19: 920-926.
56. Fuchs HF, Laughter V, Harnsberger CR, et al. (2016) Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success. Surg Endosc 30: 251-258.
57. Gadde KM, Kopping MF, Wagner HR, et al. (2012). Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 172: 1557-1564.
58. Ghanizadeh A, Nikseresht MS, Sahraian A, (2013) The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res 147: 110-115.
59. Gilbody S, Peckham E, Man M-S, et al. (2015) Bespoke smoking cessation for people with severe mental ill health (SCIMITAR): a pilot randomised controlled trial. Lancet Psychiatry 2: 395-402.
60. Goodall E, Oxtoby C, Richards R, et al. (1988) A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic induced obesity. Br J Psychiatry 153: 208-213.
61. Government Office for Science (2007) Foresight: Tackling obesities-future choices project. London: Government Office for Science. Available at: www.gov.uk/government/publications/reducing-obesity-future-choices (. accessed 3 April 2016).
62. Graham KA, Gu H, Lieberman JA, et al. (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744-1746.
63. Green AI, Brunette MF, Dawson R, et al. (2015a) Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry 76 (10): 1359-1365.
64. Green CA, Yarborough BJH, Leo MC, et al. (2015b) The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 172: 71-81.
65. Hahn MK, Remington G, Bois D, et al. (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30: 706-710.
66. Hamoui N, Kingsbury S, Anthone GJ, et al. (2004) Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg 14: 349-352.
67. Hannon TS, Arsalanian SA, (2015) The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann NY Acad Sci 1353: 113-137.
68. Hartmann-Boyce J, Aveyard P, (2016) Drugs for smoking cessation. BMJ 352: i571.
69. Hasan A, Falkai P, Wobrock T, et al. (2013) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14: 2-44.
70. Heald AH, Martin JL, Payton T, et al. (2016) Changes in metabolic parameters in patients with severe mental illness over a 10-year period: a retrospective cohort study. Aust NZ J Psychiatry. Epub ahead of print. DOI: 10.1177/0004867415625817.
71. Henderson DC, Cagliero E, Copeland PM, et al. (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry 62: 19-28.
72. Henderson DC, Kunkel L, Nguyen DD, et al. (2006) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113: 142-147.
73. Henderson DC, Fan X, Copeland PM, et al. (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29: 165-169.
74. Hilger E, Quiner S, Ginzel I, et al. (2002) The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 22: 68-70.
75. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. (2007) Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335: 136.
76. Hoffmann VP, Case M, Jacobson JG, (2012) Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry 73: 216-223.
77. Hoghton M, RCGP Learning Disabilities Group (2010) A Step by Step Guide for GP Practices: Annual Health Checks for People with a Learning Disability. London: Royal College of General Practitioners.
78. Holman RR, Sourij H, Califf RM, (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383: 2008-2017.
79. Holt RI, Mitchell AJ, (2015) Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 11: 79-89.
80. Holt RI, Pendlebury J, Wildgust HJ, et al. (2010) Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J Clin Psychiatry 71: 800-805.
81. Horst WD, Klein MW, Williams D, et al. (2005) Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatric Dis Treat 1: 349-355.
82. Hughes JR, Hatsukami DK, Mitchell JE, et al. (1986) Prevalence of smoking among psychiatric patients. Am J Psychiatry 143: 993-997.
83. Hunt GE, Siegfried N, Morley K, et al. (2013) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 10: CD001088. DOI: 10.1002/14651858.CD001088.pub3.
84. InterAct Consortium (2014) Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations. Diabetes Care 37: 3164-3171.
85. Ishoy PL, Knop FK, Vilsboll T, et al. (2013) Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type-2 diabetes. Am J Psychiatry 170: 681-682.
86. Jarskog LF, Hamer RM, Catellier DJ, et al.; for the METS Investigators (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170: 1032-1040.
87. Joffe G, Takala P, Tchoukhine E, et al. (2008). Orlistat in clozapine- or olanzapine treated patients with overweight or obesity: a 16-week randomized, double-blind placebo-controlled trial. J Clin Psychiatry 9: 706-711.
88. Johnson DE, Yamazaki H, Ward KM, et al. (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54: 1552-1558.
89. Kahn RS, Fleischhacker WW, Boter H, (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097.
90. Kelly C, McCreadie R, (2000) Cigarette smoking and schizophrenia. Adv Psychiatr Treatment 6: 327-331.
91. Kelly DL, Gorelick DA, Conley RR, et al. (2011) Effects of a cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 31: 86-91.
92. Khazaal Y, Chatton A, Rusca M, et al. (2007) Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review. Gen Hosp Psychiatry 29: 446-449.
93. Kim JH, Yim SJ, Nam JH, (2006) A 12-week randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82: 115-117.
94. Kinon BJ, Kaiser CJ, Ahmed S, (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25: 255-258.
95. Klein DJ, Cottingham EM, Sorter M, et al. (2006) A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163: 2072-2079.
96. Knott CS, Coombs N, Stamatakis E, et al. (2015) All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ 350: h384.
97. Ko YH, Joe SH, Jung IK, et al. (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28: 169-175.
98. Koskinen J, Löhönen J, Koponen H, et al. (2009) Prevalence of alcohol use disorders in schizophrenia-a systematic review and meta-analysis. Acta Psychiatr Scand 120: 85-96.
99. Kramer CK, Leitao C, Pinto LC, et al. (2011) Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 12: e338-e347. DOI: 10.1111/j.1467-789X.2010.00846.x.
100. Kryzhanovskaya LA, Xu W, Millen BA, et al. (2012) Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolescent Psychopharmacol 22: 157-165.
101. Lawrence D, Hancock KJ, Kisely S, (2013) The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 346: f2539.
102. Lester H, Marshall M, Jones P, et al. (2011) Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv 62: 882-887.
103. Lett TA, Wallace TJ, Chowdhury NI, et al. (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17: 242-266.
104. Leucht S, Cipriani A, Spineli L, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382: 951-962.
105. Liang C-S, Yang F-W, Huang S-Y, et al. (2014) Continuing weight-loss effect after topiramate discontinuation in obese persons with schizophrenia: a pilot open-label study. Pharmacopsychiatry 47: 162-168.
106. Lingford-Hughes AR, Welch S, Peters L, et al. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 26: 899-952.
107. Loring DW, Williamson DJ, Meador KJ, et al. (2011) Topiramate dose effects on cognition. A randomized double-blind study. Neurology 76: 131-137.
108. Lovell K, Wearden A, Bradshaw T, et al. (2014) An exploratory randomised controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity improve diet and reduce weight gain (INTERACT) study. J Clin Psychiatry 75: 498-505.
109. Lykkegaard K, Larsen PJ, Vrang N, et al. (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103: 94-103.
110. Maayan L, Correll CU, (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21: 517-535.
111. Maayan L, Vakhrusheva J, Correll CU, (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35: 1520-1530.
112. McCreadie RG, on behalf of the Sottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry 183: 534-539.
113. McQuade RD, Stock E, Marcus R, et al. (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomised, double-blind study. J Clin Psychiatry 65: 47-56.
114. Mahmood S, Booker I, Huang J, et al. (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90-94.
115. Manu P, Dima L, Shulman M, (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 132: 97-108.
116. Migliardi G, D'Arrigo C, Santoro V, et al. (2007) Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 30: 107-113.
117. Minutolo G, Caponnetto P, Auditore R, et al. (2013) Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. Eur Neuropsychopaharmacol 23 (Suppl 2): S581-S582.
118. Mitchell AJ, Malone D, Doebbeling CC, (2009) Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 194: 491-499.
119. Mitchell AJ, Vancampfort D, DeHerdt A, et al. (2013) Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39: 295-305.
120. Mizuno Y, Suzuki T, Nakagawa A, et al. (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40: 1385-1403.
121. Modabbernia A, Heidari P, Soleimani R, et al. (2014) Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res 53: 133-140.
122. Moore M, Hopkins J, Wainwright P, (2016) Primary care management of patients after weight loss surgery. BMJ 352: i945.
123. Mukundan A, Faulkner G, Cohn T, et al. (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 12: CD006629. DOI: 10.1002/14651858.CD006629.pub2.
124. Muscatello MRA, Bruno A, Pandolfo G, et al. (2011) Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. Schizophr Res 127: 93-99.
125. Myles N, Newall HD, Curtis J, et al. (2012) Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry 73: 468-475.
126. Narula PK, Rehan HS, Unni KES, et al. (2010) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118: 218-223.
127. Newcomer JW, (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1-93.
128. Newcomer JW, Haupt DW, Fucetola R, et al. (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337-345.
129. NHS England (2015) Commissioning for Quality and Innovation (CQUIN) Guidance for 2015/16. London: NHS England. Available at: www.england.nhs.uk/wp-content/uploads/2015/03/9-cquin-guid-2015-16.pdf (. accessed 3 April 2016).
130. NICE (2002) Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE Clinical Practice Guideline 1. London: National Institute for Health and Care Excellence.
131. NICE (2009) Psychosis and schizophrenia: management. NICE Clinical Guideline 82. London: National Institute for Health and Care Excellence.
132. NICE (2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. NICE Clinical Guideline 115. London: National Institute for Health and Care Excellence.
133. NICE (2012) Type 2 diabetes: prevention in people at high risk. NICE Public Health Guideline 38. London: National Institute for Health and Care Excellence.
134. NICE (2013) Psychosis and schizophrenia in children and young people: recognition and management. NICE Clinical Guideline 155. London: National Institute for Health and Care Excellence.
135. NICE (2014a) Psychosis and schizophrenia in adults: prevention and management. NICE Clinical Guideline 178. London: National Institute for Health and Care Excellence.
136. NICE (2014b) Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Clinical Guideline 181. London: National Institute for Health and Care Excellence.
137. NICE (2014c) Bipolar disorder: assessment and management. NICE Clinical Guideline 185. London: National Institute for Health and Care Excellence.
138. NICE (2014d) Obesity: identification, assessment and management. NICE Clinical Guideline 189. London: National Institute for Health and Care Excellence.
139. NICE (2015a) Obesity: identification, assessment and management. NICE Guideline 28. London: National Institute for Health and Care Excellence.
140. NICE (2015b) Psychosis and schizophrenia in adults. NICE Quality Standard 80. London: National Institute for Health and Care Excellence.
141. NICE (2015c) Psychosis and schizophrenia in children and young people. Evidence update 76. London: National Institute for Health and Care Excellence.
142. Nickel MK, Nickel C, Muehlbacher M, et al. (2005) Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 25: 211-217.
143. Olfson M, Gerhard T, Huang C, (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72: 1172-1181.
144. Osborn DPJ, Levy G, Nazareth I, et al. (2007a) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Arch Gen Psychiatry 64: 242-249.
145. Osborn DP, Nazareth I, King MB, (2007b) Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: a cross sectional comparative study in primary care. Soc Psychiatry and Psychiatr Epidemiol 42: 787-793.
146. Osborn D, Hardoon S, Omar RZ, et al. (2015) Cardiovascular risk prediction models for people with severe mental illness. Results from the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) Research Program. JAMA Psychiatry 72: 143-151.
147. Padwal R, Kezouh A, Levine M, et al. (2007) Long-term persistence with orlistat and sibutramine in a population based cohort. Int J Obes 31: 1567-1570.
148. Park MH, Kinra S, Ward KJ, et al. (2009) Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32: 1743-1745.
149. Patel MX, Bishara D, Jayakumar S, et al. (2014) Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 24: 499-509.
150. Petrakis IL, Nich C, Ralevski E, (2006) Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 32: 644-654.
151. Pope A, Adams C, Paton C, et al. (2010) Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry 197: 67-72.
152. Poyurovsky M, Isaacs I, Fuchs C, et al. (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160: 297-302.
153. Poyurovsky M, Fuchs C, Pashinian A, et al. (2007) Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacol 192: 441-448.
154. Poyurovsky M, Fuchs C, Pashinian A, et al. (2013) Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacol 226: 615-622.
155. Praharaj SK, Sharma PSVN, (2012) Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol 2: 151-156.
156. Public Health England (2016) NHS Health Check: best practice guidance. London: Public Health England. (PHE publications gateway number: 2015710.)
157. Puska P, Vartiainen E, Tuomilehto J, et al. (1998) Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bull WHO 76: 419-425.
158. Raskind MA, Burke BL, Crites NJ, et al. (2007) Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32: 284-288.
159. Reeves GM, Keeton C, Correll CU, et al. (2013) Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health 7: 31. Available at: www.capmh.com/content/7/1/31 (. accessed 3 April 2015).
160. Reilly S, Planner C, Hann M, et al. (2012) The Role of primary care in service provision for people with severe mental illness in the United Kingdom. PLoS ONE 7 (5): e36468. doi: 10.1371/journal.pone.0036468
161. Reynolds GP, (2012) The pharmacogenetics of antipsychotic drug-induced weight gain-a critical review. Clin Psychopharmacol Neurosci 10: 71-77.
162. Reynolds GP, Kirk SL, (2010) Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125: 169-179.
163. Roffeei SN, Reynolds GP, Zainal NZ, et al. (2014) Association of ADR2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole and ziprasidone. Hum Psychopharmacol 29: 38-45.
164. Romo-Nava F, Alvarez-Icaza Gonzalez D, Fresan-Orellana A, et al. (2014) Melatonin attenuates antipsychotic metabolic effect: an eight-week randomised, double-blind, parallel-group, placebo-controlled trial. Bipolar Disord 16: 410-421.
165. Royal College of Psychiatrists (2010) No health without public mental health: the case for action. Position Statement PS04/2010. London: Royal College of Psychiatrists.
166. Royal College of Psychiatrists (2012) Report of the National audit of Schizophrenia (NAS) 2012. London: Healthcare Quality Improvement Partnership.
167. Royal College of Psychiatrists (2013) Whole-person care: from rhetoric to reality (Achieving parity between mental and physical health). Occasional paper OP88/2013. London: Royal College of Psychiatrists.
168. Royal College of Psychiatrists (2014) Report of the second round of the National audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership.
169. Rucker D, Padwal R, Li SK, et al. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194-1199.
170. Rummel-Kluge C, Komossa K, Schwarz S, et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123: 225-233.
171. Ryan MC, Collins P, Thakore JH, (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
172. Schizophrenia Commission (2012) The abandoned illness: a report from the Schizophrenia Commission. London: Rethink Mental Illness.
173. Shekelle PG, Woolf SH, Eccles M, et al. (1999) Developing guidelines. BMJ 318: 593-596.
174. Shelby SR, Labott S, Stout RA, (2015) Bariatric surgery: a viable treatment option for patients with severe mental illness. Surg Obes Relat Dis 11: 1342-1348.
175. Shiers DE, Rafi I, Cooper SJ, et al. (2014) Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version). London: Royal College of Psychiatrists.
176. Silvestre JS, Prous J, (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27: 289-304.
177. Simon V, van Winkel R, De Hert M, (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70: 1041-1050.
178. Siris SG, (1990) Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16: 111-122.
179. Smith J, Williams B, Band M, et al. (2014) SHAPE (Supporting Health and Promoting Exercise) project for young people with psychosis. Early Interv Psychiatry 8 (Suppl S1): 30.
180. Snigdha S, Thumbi C, Reynolds GP, et al. (2008) Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 22: 567-571.
181. Spina E, Avenoso A, Scordo MG, et al. (2001) No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monitoring 23: 675-678.
182. Stahl SM, Cucchiaro J, Simonelli D, et al., (2013) Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 74: 507-515.
183. Stokes C, Peet M, (2004) Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci 7: 247-249.
184. Stroup TS, McEvoy JP, Ring KD, et al. (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168: 947-956.
185. Tatum WO, French JA, Faught E, et al. (2001) Postmarketing experience with topiramate and cognition. Epliepsia 42: 1134-1140.
186. Taylor D, Paton C, Kapur S, (2012) The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. London: Wiley-Blackwell. ISBN: 978-0-470-97948-8.
187. Tchoukhine E, Takala P, Hakko H, et al. (2011) Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomised controlled trial. J Clin Psychiatry 72: 326-330.
188. Templeman LA, Reynolds GP, Arranz B, et al. (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in caucasian subjects with a first-episode psychosis. Pharmacogenet Genom 15: 195-200.
189. Thompson J, Baxendale SA, Duncan JS, et al. (2000) Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69: 636-641.
190. Tidey JW, Miller ME, (2015) Smoking cessation and reduction in people with chronic mental illness. BMJ 351: h4065.
191. Tiihonen J, Halonen P, Wahlbeck K, et al. (2005) Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66: 1012-1015.
192. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. (2009) 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620-627.
193. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
194. Vancampfort D, Wampers M, Mitchell AJ, et al. (2013) A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 12: 240-250.
195. Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, (2015) Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 76: e1417-e1423.
196. Wang PW, Hill SJ, Childers ME, et al. (2011) Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. J Psychiatr Res 45: 1128-1132.
197. Wannamethee SG, Shaper AG, Perry IJ, British Regional Heart Study (2001). Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 24 (9): 1590-1595.
198. Weiden PJ, Mackell JA, McDonnell DD, (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66: 51-57.
199. Weiden PJ, Newcomer JW, Loebel AD, et al. (2008) Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33: 985-994.
200. Wellmer J, Wellmer S, Bauer J, (2009) The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 119: 233-238.
201. Willi C, Bodenmann P, Ghali WA, et al. (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298: 2654-2664.
202. Williams JM, Foulds J, (2007) Successful tobacco dependence treatment in schizophrenia. Am J Psychiatry 164: 222-227.
203. Wilson PWF, D'Agostino RB, Levy D, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847.
204. World Health Organization (2010) Hidden cities: unmasking and overcoming health inequities in urban settings. Switzerland: WHO Press. ISBN 978 92 1 132278 1.
205. Wu RR, Zhao JP, Guo XF, et al. (2008) Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165: 352-358.
206. Wu RR, Jin H, Gao K, et al. (2012) Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 169: 813-821.
207. Yang J, Lee MS, Joe SH, et al. (2010) Zonisamide-induced weight loss in schizophrenia: case series. Clin Neuropharmacol 33: 104-106.
208. Yevtushenko OO, Cooper SJ, O'Neill R, et al. (2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192: 424-428.
209. Zhang ZJ, Yao ZJ, Liu W, et al. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58-62.